LITESPARK-011: Belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy Review

  


Authors: Motzer, R. J.; Schmidinger, M.; Eto, M.; Suarez, C.; Figlin, R.; Liu, Y.; Perini, R.; Zhang, Y.; Heng, D. Y. C.
Review Title: LITESPARK-011: Belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy
Abstract: The first-in-class, small molecule HIF-2α inhibitor, belzutifan, has demonstrated promising antitumor activity in previously treated patients with clear cell renal cell carcinoma (RCC). HIF-2α also regulates VEGF expression and is involved in resistance to anti-VEGF therapy. This study describes the rationale and design for a randomized, phase III study evaluating efficacy and safety of belzutifan plus the tyrosine kinase inhibitor (TKI) lenvatinib versus the TKI cabozantinib in patients with advanced RCC progressing after anti-PD-1/PD-L1 therapy in the first- or second-line setting or as adjuvant therapy. Considering the unmet need for effective and tolerable treatment of advanced RCC following immune checkpoint inhibitors, belzutifan plus lenvatinib may have a positive benefit/risk profile. © 2023 Merck & Co., Inc.
Keywords: protein kinase inhibitor; basic helix-loop-helix transcription factors; pathology; renal cell carcinoma; kidney neoplasms; protein kinase inhibitors; kidney tumor; carcinoma, renal cell; metastatic; programmed death 1 ligand 1; clear cell renal cell carcinoma; basic helix loop helix transcription factor; immune checkpoint inhibitor; cabozantinib; lenvatinib; humans; human; b7-h1 antigen; pd-1/pd-l1 inhibitor; hif-2α inhibitor; belzutifan
Journal Title: Future Oncology
Volume: 19
Issue: 2
ISSN: 1479-6694
Publisher: Future Medicine  
Date Published: 2023-01-01
Start Page: 113
End Page: 121
Language: English
DOI: 10.2217/fon-2022-0802
PUBMED: 36752726
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152603156&doi=10.2217%2ffon-2022-0802&partnerID=40&md5=907613e65f068f1fe2b60b8017164405
Notes: Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Robert Motzer -- Export Date: 1 May 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
Related MSK Work